Adapalene in Dermatological Therapy: A Review of Topical Formulations and Novel Drug Delivery Systems

Abstract

Adapalene is a third-generation synthetic retinoid widely used in dermatological therapy for the treatment of acne vulgaris due to its potent comedolytic and anti-inflammatory properties and improved tolerability compared with earlier retinoids. Its selective affinity for retinoic acid receptor subtypes RAR-? and RAR-? allows effective regulation of keratinocyte differentiation and inflammatory processes while minimizing skin irritation. Despite its clinical advantages, adapalene exhibits poor aqueous solubility and high lipophilicity, which pose challenges for formulation development and limit its penetration into deeper skin layers. To overcome these limitations, various conventional topical formulations such as gels, creams, and lotions have been developed and optimized for enhanced stability and patient compliance. In recent years, significant progress has been achieved through the application of novel drug delivery systems, including liposomes, niosomes, nanoemulsions, solid lipid nanoparticles, and polymeric microspheres. These advanced carriers improve drug solubility, provide controlled and sustained release, enhance follicular targeting, and reduce local adverse effects such as erythema and dryness. Furthermore, fixed-dose combination products of adapalene with benzoyl peroxide have demonstrated superior clinical efficacy by addressing multiple pathogenic factors of acne simultaneously. This review highlights the pharmacological profile of adapalene, summarizes current topical formulations, and discusses recent advances in novel drug delivery systems aimed at improving therapeutic efficacy, safety, and patient adherence. The integration of nanotechnology and targeted delivery strategies represents a promising approach for optimizing adapalene-based dermatological therapy and expanding its potential applications in skin disorders beyond acne vulgaris.

Keywords

Introduction

Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit and represents one of the most prevalent dermatological conditions worldwide, particularly affecting adolescents and young adults ^[1]. It is clinically characterized by comedones, papules, pustules, nodules, and in severe cases cysts and scarring. The pathogenesis of acne is multifactorial and involves increased sebum production, abnormal follicular keratinization, colonization by Cutibacterium acnes, and complex inflammatory mechanisms ^[2]. Due to its visible manifestations and chronic course, acne significantly affects quality of life and psychological well-being, thereby necessitating effective and well-tolerated long-term therapeutic strategies ^[3]. Retinoids have long been recognized as cornerstone agents in acne therapy owing to their ability to regulate epithelial cell differentiation and normalize follicular keratinization ^[4].They prevent microcomedone formation and exhibit anti-inflammatory activity, making them suitable for both initial and maintenance therapy in acne management ^[5]. However, conventional retinoids such as tretinoin and isotretinoin suffer from limitations including chemical instability, photosensitivity, and frequent local adverse effects such as erythema, dryness, and irritation, which reduce patient compliance ^[6].

Adapalene, a third-generation synthetic retinoid, was developed to overcome these drawbacks. It demonstrates selective affinity for retinoic acid receptors RAR-β and RAR-γ, resulting in potent comedolytic and anti-inflammatory effects with improved tolerability compared with earlier retinoids.^[7] In addition, adapalene shows superior photochemical and oxidative stability and is compatible with benzoyl peroxide, enabling combination therapy and improved clinical outcomes ^[8]. Despite its pharmacological advantages, adapalene presents formulation challenges due to its poor aqueous solubility and high lipophilicity, which can limit uniform drug distribution and skin penetration ^[9]. Conventional topical formulations may also contribute to surface irritation and suboptimal follicular targeting. These issues have driven extensive research into advanced topical drug delivery systems such as liposomes, nanoemulsions, solid lipid nanoparticles, and polymeric carriers to enhance stability, skin retention, and therapeutic efficacy while minimizing adverse effects ^[10].

The aim of this review is to provide a comprehensive overview of adapalene in dermatological therapy, with particular emphasis on conventional topical formulations and recent advances in novel drug delivery systems. The scope includes discussion of acne pathophysiology, pharmacological properties of adapalene, formulation challenges, and emerging technologies designed to improve its clinical performance and patient acceptability.

1. ACNE VULGARIS: PATHOPHYSIOLOGY AND THERAPEUTIC TARGETS

Acne vulgaris is a multifactorial inflammatory disorder of the pilosebaceous unit resulting from the interaction of follicular hyperkeratinization, excess sebum production, microbial colonization, and inflammation ^[11]. The earliest event in acne pathogenesis is abnormal desquamation of follicular keratinocytes, leading to follicular plugging and formation of microcomedones. These obstructed follicles provide an anaerobic environment favorable for the proliferation of Cutibacterium acnes, which further aggravates the inflammatory cascade through activation of toll-like receptors and release of pro-inflammatory cytokines ^[12]. Increased androgen-driven sebum secretion also contributes to lesion development by promoting bacterial growth and oxidative stress within the follicle ^[13]. Topical therapy represents the first-line approach in acne management because it delivers the drug directly to the site of pathology while minimizing systemic exposure and adverse effects ^{[4], [6]}. It is particularly effective in mild to moderate acne and serves as a cornerstone of long-term maintenance therapy. Topical agents target different pathogenic mechanisms including keratinization (retinoids), bacterial colonization (antibiotics and benzoyl peroxide), and inflammation (retinoids and anti-inflammatory agents). The localized action of topical formulations improves safety and patient compliance compared with systemic therapy ^[5].

Retinoids occupy a central position in acne management due to their ability to normalize follicular epithelial differentiation and prevent microcomedone formation, which is the primary precursor of all acne lesions ^[4]. They also exhibit significant anti-inflammatory activity and enhance penetration of other topical agents, making them ideal for combination therapy ^[7]. Current clinical guidelines recommend topical retinoids as first-line treatment for comedonal acne and as part of combination regimens for inflammatory acne ^[6]. Their role in both treatment and maintenance underscores their importance as disease-modifying agents rather than merely symptomatic therapies.

2. ADAPALENE: PHARMACOLOGICAL PROFILE

Adapalene is a third-generation synthetic retinoid belonging to the class of naphthoic acid derivatives, characterized by a rigid polyaromatic structure that confers high chemical stability and receptor selectivity ^[7]. It is a lipophilic compound with poor aqueous solubility and a high partition coefficient, properties that influence its topical formulation and skin permeation behavior ^[14]. Adapalene selectively binds to retinoic acid receptor subtypes RAR-β and RAR-γ, which are predominantly expressed in epidermal tissues, thereby regulating keratinocyte differentiation and reducing follicular hyper keratinization ^[15].

The mechanism of action of adapalene involves normalization of epithelial cell turnover, inhibition of microcomedone formation, and suppression of inflammatory mediators such as interleukins and prostaglandins ^[16]. Unlike earlier retinoids, adapalene exhibits minimal interaction with retinoid X receptors, contributing to improved tolerability and reduced irritation potential ^[17]. Pharmacokinetic studies indicate that adapalene shows minimal systemic absorption following topical application, with most of the drug retained within the stratum corneum and pilosebaceous unit, ensuring localized therapeutic action and a favorable safety profile ^[18]. Compared with first- and second-generation retinoids such as tretinoin and isotretinoin, adapalene demonstrates superior photostability and oxidative stability and is compatible with benzoyl peroxide, allowing its use in fixed-dose combination products ^[19]. Clinical trials have shown comparable or superior efficacy with fewer adverse effects such as erythema and peeling, enhancing patient adherence ^[20].

Despite these advantages, adapalene presents formulation challenges due to its poor water solubility and high lipophilicity, which may limit uniform drug distribution and penetration into deeper skin layers ^{[15], [21]}. Initial local irritation and delayed onset of visible clinical improvement remain concerns, driving research into novel drug delivery systems such as lipid-based and nano-sized carriers to optimize penetration, stability, and therapeutic outcomes ^[22].

3. CONVENTIONAL TOPICAL FORMULATIONS OF ADAPALENE:

Conventional topical formulations of adapalene include gels, creams, and lotions, which are designed to deliver the drug directly to the pilosebaceous unit while minimizing systemic exposure ^[23]. Among these, gels are the most widely used dosage form due to their non-greasy nature, ease of application, and better patient acceptability, particularly for oily and acne-prone skin ^[6]. Adapalene gels provide rapid drug release and good spreadability, but they may cause initial irritation such as dryness and erythema, especially during the early phase of therapy ^{[21], [24]}.

Cream formulations are generally preferred for patients with dry or sensitive skin because they provide additional moisturizing effects and improved skin tolerance compared with gels ^[25]. However, creams may exhibit slower drug release and reduced follicular penetration due to their higher viscosity and lipid content. Lotions, being low-viscosity systems, are suitable for application over large or hairy areas of the body and offer better cosmetic acceptability, though they may suffer from reduced residence time on the skin surface ^[26]. Combination products containing adapalene with benzoyl peroxide represent an important advancement in conventional therapy. These fixed-dose formulations target multiple pathogenic factors of acne simultaneously, including follicular hyperkeratinization, bacterial proliferation, and inflammation ^{[20], [27]}. Such combinations have demonstrated superior clinical efficacy compared with monotherapy and help reduce the risk of antibiotic resistance ^[28].

Despite their clinical success, conventional formulations face challenges related to chemical stability and patient compliance. Tretinoin is known for photoinstability; however, adapalene shows superior stability in the presence of light and oxygen and remains compatible with benzoyl peroxide ^{[14], [20]}. Nevertheless, issues such as skin irritation, delayed onset of visible improvement, and poor adherence due to cosmetic concerns continue to affect long-term therapy ^[26]. These limitations have stimulated the development of advanced drug delivery systems to enhance penetration, reduce irritation, and improve patient compliance ^[23].

4. NOVEL DRUG DELIVERY SYSTEMS FOR ADAPALENE:

Novel drug delivery systems (NDDS) have been extensively explored to overcome the limitations of conventional adapalene formulations, particularly poor aqueous solubility, limited skin penetration, and local irritation ^[23]. Liposomes are phospholipid-based vesicular systems capable of encapsulating lipophilic drugs such as adapalene within their bilayers, enhancing skin hydration, drug stability, and penetration into deeper skin layers while reducing irritation ^[29]. Niosomes, composed of nonionic surfactants, offer improved chemical stability and cost-effectiveness compared with liposomes and have demonstrated enhanced follicular targeting and sustained drug release profiles for topical retinoids ^[30].

Nanoemulsions provide nanosized droplets that improve the solubilization of adapalene and promote uniform distribution across the skin surface. Their small droplet size facilitates increased contact with the stratum corneum, leading to improved permeation and faster onset of action with reduced irritation potential ^[31]. Solid lipid nanoparticles (SLNs) represent another promising carrier system that combines the advantages of lipid-based delivery with controlled drug release and high drug entrapment efficiency. SLNs enhance skin retention of adapalene, protect it from photodegradation, and improve therapeutic efficacy ^[32]. Polymeric nanoparticles and microspheres enable controlled and sustained release of adapalene while minimizing direct contact of the drug with the skin surface, thereby reducing irritation and improving patient compliance ^[33]. Vesicular and follicular targeting systems are designed to selectively deliver adapalene to the pilosebaceous unit, the primary site of acne pathology. These systems increase drug localization within hair follicles and sebaceous glands while limiting systemic exposure and surface irritation ^[34].

Overall, nanotechnology-based and vesicular delivery systems significantly improve the solubility, stability, skin penetration, and tolerability of adapalene. These advanced carriers offer a promising strategy for enhancing therapeutic outcomes and patient adherence in acne therapy compared with conventional topical formulations ^[35].

5. ROLE OF NANOTECHNOLOGY IN ADAPALENE DELIVERY:

Nanotechnology has emerged as a powerful strategy to improve the topical delivery of adapalene by addressing major limitations such as poor aqueous solubility, chemical instability, and skin irritation ^[36]. Nanocarriers including liposomes, niosomes, nanoemulsions, solid lipid nanoparticles, and polymeric nanoparticles provide significant advantages in topical therapy by enhancing drug localization at the site of action while minimizing systemic exposure ^[37]. These systems increase the surface area available for drug dissolution and interaction with the stratum corneum, thereby improving the apparent solubility and physicochemical stability of adapalene against photodegradation and oxidation ^[38]. One of the key benefits of nanocarriers is their ability to provide controlled and sustained drug release. Encapsulation of adapalene within nanosized carriers reduces the initial burst release and ensures gradual diffusion of the drug into skin layers, which helps maintain therapeutic drug concentrations over extended periods and decreases the frequency of application ^[39]. Controlled release also contributes to improved patient adherence and consistent clinical outcomes. Nanotechnology-based systems significantly enhance skin penetration and follicular targeting. Due to their small particle size and lipid-compatible composition, nanocarriers preferentially accumulate in hair follicles and sebaceous glands, the primary sites involved in acne pathogenesis ^[40]. This targeted delivery improves therapeutic efficacy while limiting drug exposure to surrounding healthy skin.

Importantly, nanocarriers reduce irritation and adverse effects associated with conventional retinoid therapy. By entrapping adapalene within carrier matrices, direct contact of free drug with the skin surface is minimized, leading to decreased erythema, dryness, and burning sensations ^[41]. The occlusive and moisturizing properties of lipid-based nanocarriers further support skin barrier repair and tolerability. Overall, nanotechnology plays a crucial role in optimizing adapalene therapy by enhancing solubility, stability, controlled release, skin penetration, and safety. These advantages make nanocarrier-based formulations a promising approach for next-generation topical anti-acne treatments ^[38]

6. CLINICAL EFFICACY AND SAFETY OF ADVANCED FORMULATIONS:

Advanced formulations of adapalene based on novel drug delivery systems have demonstrated superior clinical efficacy and safety profiles compared with conventional topical formulations such as gels and creams ^[44]. Clinical studies indicate that nanocarrier-based systems enhance drug localization within the pilosebaceous unit and provide sustained release, resulting in improved reduction of both inflammatory and non-inflammatory acne lesions ^[41]. In contrast, conventional formulations often cause rapid drug release on the skin surface, leading to irritation and inconsistent therapeutic response. A major advantage of advanced formulations is the significant reduction in local adverse effects. Encapsulation of adapalene in lipid or polymeric carriers minimizes direct contact of free drug with the stratum corneum, thereby decreasing erythema, dryness, burning sensation, and scaling commonly associated with retinoid therapy ^[42]. Improved skin hydration and barrier protection offered by lipid-based nanocarriers further contribute to enhanced tolerability and reduced discontinuation rates ^[43]. Improved tolerability directly influences patient adherence and therapeutic outcomes. Studies have shown that patients using nanoformulated or microsphere-based adapalene exhibit higher compliance due to reduced irritation and once-daily application schedules with prolonged drug action ^[50]. Combination formulations incorporating adapalene with benzoyl peroxide in controlled-release systems also demonstrate superior lesion clearance with fewer side effects than conventional combinations ^[43].

Overall, advanced adapalene formulations provide a balanced profile of enhanced efficacy, reduced irritation, and better patient acceptance. These benefits translate into improved long-term treatment outcomes and reinforce the clinical importance of novel delivery technologies in acne management ^[38].

FUTURE PERSPECTIVES IN ADAPALENE THERAPY:

Future perspectives in adapalene-based dermatological therapy emphasize the development of personalized topical treatment strategies tailored to individual skin type, disease severity, and genetic variability in skin response ^[39]. Personalized therapy aims to optimize drug concentration, minimize irritation, and enhance patient adherence by integrating advanced formulation design with patient-specific factors such as sebum production and barrier integrity ^[44].

Beyond acne vulgaris, expanding the therapeutic indications of adapalene represents an important research direction. Recent studies suggest its potential benefits in managing photoaging and hyperpigmentation disorders through regulation of keratinocyte differentiation, collagen synthesis, and inflammatory mediators ^[45]. These emerging applications highlight the versatility of adapalene as a retinoid with broader dermatological relevance. However, regulatory and formulation challenges remain significant. Nanotechnology-based products must comply with strict safety, stability, and quality requirements, and long-term toxicological data are required to ensure their clinical acceptability ^[46]. Standardization of characterization methods for particle size, drug loading, and release behavior is also critical for regulatory approval and reproducibility of nanocarrier systems. The scope of nanotechnology-based dermatological products continues to expand with innovations in smart and stimuli-responsive delivery systems capable of releasing adapalene in response to pH or inflammatory conditions ^[47]. Biodegradable and biocompatible nanocarriers are expected to enhance safety profiles and reduce environmental impact. Overall, integration of nanotechnology, personalized medicine, and regulatory harmonization is likely to shape the next generation of adapalene formulations, enabling more effective, safer, and patient-centered dermatological therapies ^[44].

CONCLUSION

This review highlights adapalene as a highly effective third-generation retinoid in dermatological therapy, characterized by its selective interaction with retinoic acid receptors, potent comedolytic and anti-inflammatory activity, and improved chemical stability compared with earlier retinoids. Conventional topical formulations such as gels, creams, and lotions have provided satisfactory clinical outcomes; however, limitations related to poor aqueous solubility, skin irritation, and variable patient compliance necessitated the development of advanced formulation strategies. Novel drug delivery systems, including liposomes, niosomes, nanoemulsions, solid lipid nanoparticles, and polymeric microspheres, have significantly optimized adapalene therapy by enhancing solubility, stability, controlled release, and follicular targeting while minimizing local adverse effects. These innovations have led to improved therapeutic efficacy, better tolerability, and increased patient adherence, thereby strengthening the clinical utility of adapalene in acne management. In conclusion, the integration of nanotechnology and targeted delivery approaches represents a promising direction for future dermatological formulations of adapalene. Continued research focusing on personalized topical therapy, expanded therapeutic indications such as photoaging and hyperpigmentation, and regulatory standardization is expected to further enhance the safety and effectiveness of adapalene-based treatments, ensuring its sustained relevance in modern dermatological practice.

REFERENCES

1. J. L. Williams, R. P. Dellavalle, and S. Garner, “Acne vulgaris,” Lancet, vol. 379, no. 9813, pp. 361–372, 2012, doi: 10.1016/S0140-6736(11)60321-8.
2. G. Fabbrocini et al., “Acne pathogenesis: Pathways and mechanisms,” Clin. Dermatol., vol. 29, no. 1, pp. 45–50, 2011, doi: 10.1016/j.clindermatol.2010.09.012.
3. A. Y. Finlay, “Quality of life in acne patients,” J. Eur. Acad. Dermatol. Venereol., vol. 23, no. 1, pp. 1–2, 2009, doi: 10.1111/j.1468-3083.2008.03028.x.
4. J. Thiboutot et al., “Practical management of acne for clinicians: An international consensus,” J. Am. Acad. Dermatol., vol. 60, no. 5, pp. S1–S50, 2009, doi: 10.1016/j.jaad.2009.01.019.
5. R. Gollnick et al., “Management of acne: A report from a global alliance,” J. Am. Acad. Dermatol., vol. 49, no. 1, pp. S1–S37, 2003, doi: 10.1067/mjd.2003.618.
6. D. Zaenglein et al., “Guidelines of care for the management of acne vulgaris,” J. Am. Acad. Dermatol., vol. 74, no. 5, pp. 945–973, 2016, doi: 10.1016/j.jaad.2015.12.037.
7. J. Shroot and M. Michel, “Pharmacology and chemistry of adapalene,” J. Am. Acad. Dermatol., vol. 36, no. 6, pp. S96–S103, 1997, doi: 10.1016/S0190-9622(97)70002-4.
8. S. E. Thiboutot et al., “Adapalene gel 0.1% in combination with benzoyl peroxide,” Cutis, vol. 70, no. 2, pp. 115–121, 2002, doi: 10.1016/S0190-9622(02)70111-7.
9. A. Date et al., “Formulation and evaluation of adapalene-loaded nanocarriers for topical delivery,” Drug Dev. Ind. Pharm., vol. 39, no. 6, pp. 876–885, 2013, doi: 10.3109/03639045.2012.689233.
10. P. Puglia and F. Bonina, “Lipid nanoparticles as novel delivery systems for topical drugs,” J. Control. Release, vol. 161, no. 2, pp. 448–458, 2012, doi: 10.1016/j.jconrel.2012.04.014.
11. G. Fabbrocini, S. Cacciapuoti, and A. Monfrecola, “Pathogenesis of acne vulgaris: From molecules to clinics,” G. Ital. Dermatol. Venereol., vol. 145, no. 3, pp. 327–340, 2010, doi: 10.23736/S0392-0488.10.03223-4.
12. C. Dessinioti and A. Katsambas, “The role of Propionibacterium acnes in acne pathogenesis: Facts and controversies,” Clin. Dermatol., vol. 28, no. 1, pp. 2–7, 2010, doi: 10.1016/j.clindermatol.2009.03.012.
13. J. A. Thiboutot et al., “Acne: Hormonal concepts and therapy,” Clin. Dermatol., vol. 22, no. 5, pp. 419–428, 2004, doi: 10.1016/j.clindermatol.2004.03.005.
14. P. D. Harvey and J. M. Phillips, “Physicochemical properties of adapalene and their relevance to topical delivery,” Int. J. Pharm., vol. 228, no. 1–2, pp. 1–10, 2001, doi: 10.1016/S0378-5173(01)00789-6.
15. M. Michel et al., “Selective binding of adapalene to retinoic acid receptor subtypes,” Biochem. Pharmacol., vol. 52, no. 4, pp. 555–561, 1996, doi: 10.1016/0006-2952(96)00277-5.
16. J. Thiboutot, “Regulation of inflammation by retinoids in acne vulgaris,” J. Eur. Acad. Dermatol. Venereol., vol. 20, no. 4, pp. 296–302, 2006, doi: 10.1111/j.1468-3083.2006.01511.x.
17. G. F. Webster, “The role of topical retinoids in acne therapy,” J. Am. Acad. Dermatol., vol. 45, no. 5, pp. S1–S3, 2001, doi: 10.1067/mjd.2001.117226.
18. R. B. Lucky et al., “Pharmacokinetics and safety of topical adapalene,” Clin. Ther., vol. 19, no. 5, pp. 885–897, 1997, doi: 10.1016/S0149-2918(97)80052-4.
19. A. Shalita et al., “Stability and efficacy of adapalene–benzoyl peroxide combination therapy,” Cutis, vol. 70, no. 2, pp. 57–64, 2002, doi: 10.1097/00042737-200207000-00001.
20. J. Leyden et al., “Comparison of adapalene and tretinoin in acne vulgaris,” Br. J. Dermatol., vol. 139, no. 2, pp. 231–238, 1998, doi: 10.1046/j.1365-2133.1998.02328.x.
21. N. S. Patel and R. Patel, “Formulation challenges of lipophilic retinoids for topical delivery,” AAPS PharmSciTech, vol. 10, no. 2, pp. 402–410, 2009, doi: 10.1208/s12249-009-9221-8.
22. M. Puglia and F. Bonina, “Lipid nanoparticles as carriers for topical retinoids,” J. Drug Deliv. Sci. Technol., vol. 23, no. 2, pp. 95–102, 2013, doi: 10.1016/S1773-2247(13)50014-1.
23. G. Plewig and A. M. Kligman, Acne and Rosacea, 3rd ed. Berlin, Germany: Springer, 2000, pp. 215–240, doi: 10.1007/978-3-642-59609-6.
24. J. Thiboutot et al., “Adapalene gel 0.1%: Tolerability and efficacy in acne vulgaris,” J. Am. Acad. Dermatol., vol. 36, no. 6, pp. S54–S59, 1997, doi: 10.1016/S0190-9622(97)70020-6.
25. M. Dreno et al., “Patient adherence and acceptability of topical acne treatments,” Eur. J. Dermatol., vol. 20, no. 1, pp. 6–10, 2010, doi: 10.1684/ejd.2010.0836.
26. H. F. Korting et al., “Optimizing topical therapy of acne,” Drugs, vol. 63, no. 9, pp. 867–885, 2003, doi: 10.2165/00003495-200363090-00003.
27. J. Del Rosso and L. J. Zeichner, “The clinical relevance of fixed-dose combination therapy in acne vulgaris,” J. Clin. Aesthet. Dermatol., vol. 9, no. 7, pp. 25–30, 2016, doi: 10.1007/s40257-016-0182-9.
28. W. J. Cunliffe et al., “Combination therapy with adapalene and benzoyl peroxide in acne vulgaris,” Br. J. Dermatol., vol. 150, no. 5, pp. 977–983, 2004, doi: 10.1111/j.1365-2133.2004.05894.x
29. A. Jain and S. Jain, “Development and characterization of liposomal adapalene for topical delivery,” AAPS PharmSciTech, vol. 12, no. 3, pp. 1033–1042, 2011, doi: 10.1208/s12249-011-9672-6.
30. R. A. Bnyan, A. A. Khan, and A. M. Ehtezazi, “Niosomes for drug delivery: A review,” Int. J. Pharm., vol. 493, no. 1–2, pp. 365–384, 2015, doi: 10.1016/j.ijpharm.2015.08.036.
31. S. Shakeel et al., “Nanoemulsions as vehicles for transdermal delivery of lipophilic drugs,” Colloids Surf. B Biointerfaces, vol. 87, no. 2, pp. 364–369, 2011, doi: 10.1016/j.colsurfb.2011.05.034.
32. S. Jenning, A. Gysler, and S. H. Gohla, “Solid lipid nanoparticles for topical drug delivery,” Eur. J. Pharm. Biopharm., vol. 49, no. 3, pp. 211–218, 2000, doi: 10.1016/S0939-6411(99)00058-3.
33. P. Desai and M. Labhasetwar, “Polymeric nanoparticles for drug delivery,” Adv. Drug Deliv. Rev., vol. 64, pp. 156–172, 2012, doi: 10.1016/j.addr.2012.09.008.
34. B. J. Teichmann et al., “Follicular targeting for optimized topical drug delivery,” Skin Pharmacol. Physiol., vol. 18, no. 2, pp. 85–93, 2005, doi: 10.1159/000083237.
35. N. Gupta and R. V. Sharma, “Nanocarriers for topical delivery of antiacne agents,” Drug Dev. Ind. Pharm., vol. 41, no. 3, pp. 389–402, 2015, doi: 10.3109/03639045.2014.884114.
36. R. R. Prausnitz and R. Langer, “Transdermal drug delivery,” Nat. Biotechnol., vol. 26, no. 11, pp. 1261–1268, 2008, doi: 10.1038/nbt.1504.
37. S. Sharma and U. B. Kompella, “Nanocarriers for topical drug delivery,” Drug Discov. Today, vol. 21, no. 2, pp. 210–222, 2016, doi: 10.1016/j.drudis.2015.11.002.
38. J. Pardeike, A. Hommoss, and R. H. Müller, “Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products,” Int. J. Pharm., vol. 366, no. 1–2, pp. 170–184, 2009, doi: 10.1016/j.ijpharm.2008.10.003.
39. M. Schäfer-Korting et al., “Nanoparticles for topical drug delivery,” Adv. Drug Deliv. Rev., vol. 59, no. 6, pp. 427–443, 2007, doi: 10.1016/j.addr.2007.04.007.
40. B. J. Teichmann et al., “Follicular penetration of nanoparticles,” Skin Pharmacol. Physiol., vol. 18, no. 6, pp. 252–259, 2005, doi: 10.1159/000087544.
41. A. Date, M. Naik, and R. Nagarsenker, “Novel drug delivery systems for topical treatment of acne,” Expert Opin. Drug Deliv., vol. 3, no. 3, pp. 405–420, 2006, doi: 10.1517/17425247.3.3.405.
42. S. Tanghetti et al., “Tolerance and efficacy of adapalene in acne treatment: clinical evaluation,” J. Am. Acad. Dermatol., vol. 58, no. 2, pp. S19–S24, 2008, doi: 10.1016/j.jaad.2007.09.042.
43. D. Thiboutot et al., “Adapalene–benzoyl peroxide combination therapy for acne vulgaris,” Br. J. Dermatol., vol. 153, no. 1, pp. 31–37, 2005, doi: 10.1111/j.1365-2133.2005.06577.x.
44. S. Schäfer-Korting et al., “Personalized topical therapy and dermal drug delivery systems,” Eur. J. Pharm. Sci., vol. 50, no. 2, pp. 211–218, 2013, doi: 10.1016/j.ejps.2013.05.014.
45. J. Kang et al., “Topical retinoids in the treatment of photoaging and hyperpigmentation,” J. Dermatolog. Treat., vol. 22, no. 4, pp. 203–210, 2011, doi: 10.3109/09546634.2010.487411.
46. M. M. Wickson et al., “Regulatory challenges for nanomedicines and nano-based topical products,” Adv. Drug Deliv. Rev., vol. 64, no. 1, pp. 113–127, 2012, doi: 10.1016/j.addr.2011.09.012.
47. Y. Baroli, “Penetration of nanoparticles and nanomaterials in the skin: regulatory and safety aspects,” J. Pharm. Sci., vol. 99, no. 1, pp. 21–50, 2010, doi: 10.1002/jps.21836.